Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models

Wilson Nguyen; Eri Nakayama; Kexin Yan; Bing Tang; Thuy T Lee; Liang Liu; Tamara H Cooper; John D Hayball; Helen Faddy; D Warrilow; Richard J. N Allcock; Jody Hobson-Peters; Roy Hall; Daniel J Rawle; Viviana P Lutzky; Paul R Young; Nidia M Oliveira; Gunter Hartel; Paul M Howley; Natalie A Prow; Andreas Suhrbier

doi:10.3390/vaccines8020209

Back

Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models

Journal article

Open access

Peer reviewed

Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models

Wilson Nguyen, Eri Nakayama, Kexin Yan, Bing Tang, Thuy T Lee, Liang Liu, Tamara H Cooper, John D Hayball, Helen Faddy, D Warrilow, …

Vaccines, Vol.8(2), pp.1-26

2020

DOI: https://doi.org/10.3390/vaccines8020209

PMID: 32380760

Files and links (2)

pdf

Arthritogenic Alphavirus Vaccines_Serogrouping Versus Cross-Protection in Mouse Models6.27 MBDownload View

Published VersionCC BY V4.0, Open Access

url

https://doi.org/10.3390/vaccines8020209View

Published Version Open

Abstract

o’nyong nyong virus

Ross River virus

Getah virus

Mayaro virus

Chikungunya virus

Chikungunya virus (CHIKV), Ross River virus (RRV), o’nyong nyong virus (ONNV), Mayaro virus (MAYV) and Getah virus (GETV) represent arthritogenic alphaviruses belonging to the Semliki Forest virus antigenic complex. Antibodies raised against one of these viruses can cross-react with other serogroup members, suggesting that, for instance, a CHIKV vaccine (deemed commercially viable) might provide cross-protection against antigenically related alphaviruses. Herein we use human alphavirus isolates (including a new human RRV isolate) and wild-type mice to explore whether infection with one virus leads to cross-protection against viremia after challenge with other members of the antigenic complex. Persistently infected Rag1 -/- mice were also used to assess the cross-protective capacity of convalescent CHIKV serum. We also assessed the ability of a recombinant poxvirus-based CHIKV vaccine and a commercially available formalin-fixed, whole-virus GETV vaccine to induce cross-protective responses. Although cross-protection and/or cross-reactivity were clearly evident, they were not universal and were often suboptimal. Even for the more closely related viruses (e.g., CHIKV and ONNV, or RRV and GETV), vaccine-mediated neutralization and/or protection against the intended homologous target was significantly more effective than cross-neutralization and/or cross-protection against the heterologous virus. Effective vaccine-mediated cross-protection would thus likely require a higher dose and/or more vaccinations, which is likely to be unattractive to regulators and vaccine manufacturers.

Details

Title: Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models
Authors: Wilson Nguyen (Author) - QIMR Berghofer Medical Research Institute
Eri Nakayama (Author) - QIMR Berghofer Medical Research Institute
Kexin Yan (Author) - QIMR Berghofer Medical Research Institute
Bing Tang (Author) - QIMR Berghofer Medical Research Institute
Thuy T Lee (Author) - QIMR Berghofer Medical Research Institute
Liang Liu (Author) - University of South Australia
Tamara H Cooper (Author) - University of South Australia
John D Hayball (Author) - University of South Australia
Helen Faddy (Author) - Australian Red Cross Lifeblood
D Warrilow (Author) - Queensland Health Forensic and Scientific Services
Richard J. N Allcock (Author) - The University of Western Australia
Jody Hobson-Peters (Author) - The University of Queensland
Roy Hall (Author) - The University of Queensland
Daniel J Rawle (Author) - QIMR Berghofer Medical Research Institute
Viviana P Lutzky (Author) - QIMR Berghofer Medical Research Institute
Paul R Young (Author) - The University of Queensland
Nidia M Oliveira (Author) - The University of Western Australia
Gunter Hartel (Author) - QIMR Berghofer Medical Research Institute
Paul M Howley (Author) - Sementis Ltd. (Australia)
Natalie A Prow (Author) - QIMR Berghofer Medical Research Institute
Andreas Suhrbier (Author) - QIMR Berghofer Medical Research Institute
Publication details: Vaccines, Vol.8(2), pp.1-26
Publisher: MDPI AG
Date published: 2020
DOI: 10.3390/vaccines8020209
ISSN: 2076-393X
PMID: 32380760
Copyright note: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Organisation Unit: School of Health - Biomedicine; University of the Sunshine Coast, Queensland; School of Health and Sport Sciences - Legacy; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99477803702621
Output Type: Journal article

Metrics

21 File views/ downloads

70 Record Views

33 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Immunology; Medicine, Research & Experimental

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites